Molecular Formula | C17H25NO2 |
Molar Mass | 275.39 |
Density | 1.12±0.1 g/cm3(Predicted) |
Boling Point | 400.8±45.0 °C(Predicted) |
pKa | 14.95±0.40(Predicted) |
application | the new antiarrhythmic drug vinakalan (English name Vernakalant) is a dual inhibitor of atrial selective sodium/potassium channels. Jointly developed by CardionmePharma Pharmaceutical Company of Canada and AstellasPharma Pharmaceutical Company of the United States, the mechanism of action is to selectively block the sodium and potassium (Ikur) ion channels in the atrium during the attack of atrial fibrillation, and inhibit IKur current can prolong the action potential of the atrium Time course, reduce the risk of arrhythmia. Venakalan intermediates are mainly used to prepare Venakalan. |